Supernus Pharmaceuticals SUPN Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's operating lease liabilities (current)?
- Supernus Pharmaceuticals (SUPN) reported operating lease liabilities (current) of $10.64M in Q1 2026.
- How has Supernus Pharmaceuticals's operating lease liabilities (current) changed year-over-year?
- Supernus Pharmaceuticals's operating lease liabilities (current) increased by 79.1% year-over-year, from $5.94M to $10.64M.
- What is the long-term trend for Supernus Pharmaceuticals's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's operating lease liabilities (current) has grown at a 23.1% compound annual growth rate (CAGR), from $3.76M to $10.61M.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.